{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Eyes+With+Retinal+Diseases&page=13",
    "query": {
      "condition": "Eyes With Retinal Diseases",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 838,
    "total_pages": 84,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Eyes+With+Retinal+Diseases&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Eyes+With+Retinal+Diseases&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T01:44:53.336Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00065728",
      "title": "Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2003-06",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2013-09-16",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "Central Contact Fort Worth, Texas",
      "locations": [
        {
          "city": "Central Contact Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00065728"
    },
    {
      "nct_id": "NCT01792141",
      "title": "Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Macular Edema"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Retina Institute of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2011-01",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-02-15",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01792141"
    },
    {
      "nct_id": "NCT04362241",
      "title": "DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Retinopathy, Diabetic"
      ],
      "interventions": [
        {
          "name": "Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophthalmic Consultants of the Capital Region",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-08-07",
      "completion_date": "2022-03",
      "has_results": false,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "Troy, New York",
      "locations": [
        {
          "city": "Troy",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04362241"
    },
    {
      "nct_id": "NCT00623077",
      "title": "MT2004-30: Tomotherapy for Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Kidney Cancer",
        "Liver Cancer",
        "Retinoblastoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "tomotherapy",
          "type": "RADIATION"
        },
        {
          "name": "total marrow irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "Whole lung radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 23,
      "start_date": "2005-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623077"
    },
    {
      "nct_id": "NCT01875770",
      "title": "Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Vein Occlusion"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 47,
      "start_date": "2013-01",
      "completion_date": "2021-03-03",
      "has_results": false,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01875770"
    },
    {
      "nct_id": "NCT05984927",
      "title": "NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "NG101 AAV gene therapy",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Elisigen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 20,
      "start_date": "2023-09-08",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05984927"
    },
    {
      "nct_id": "NCT02162953",
      "title": "Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Disease",
        "Bestrophinopathy",
        "Best Vitelliform Macular Dystrophy",
        "Adult Onset Vitelliform Macular Dystrophy",
        "Autosomal Dominant Vitreoretinalchoroidopathy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2014-02",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-09",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02162953"
    },
    {
      "nct_id": "NCT00130845",
      "title": "Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Octreotide Acetate in Microspheres",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 312,
      "start_date": "2000-02",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2011-11-17",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130845"
    },
    {
      "nct_id": "NCT00395057",
      "title": "A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroid Neovascularization",
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "AGN 211745",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab 500µg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2007-01",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2015-09-07",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00395057"
    },
    {
      "nct_id": "NCT04740671",
      "title": "A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "HLX04-O",
          "type": "DRUG"
        },
        {
          "name": "ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shanghai Henlius Biotech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2021-07-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-01-03",
      "last_synced_at": "2026-10-25T01:44:53.336Z",
      "location_count": 42,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Fullerton, California + 34 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04740671"
    }
  ]
}